These medications are primarily used in the management of type 2 diabetes. Certain formulations are also approved for chronic weight management in eligible individuals. Their effects depend on the specific medication, dosage, and individual health circumstances.
Key mechanisms of GLP1 receptor agonists include:
Insulin secretion: They stimulate insulin release from pancreatic beta cells when blood glucose levels are elevated.
Glucagon regulation: They reduce glucagon secretion when it is not needed, helping control glucose production by the liver.
Gastric emptying: They slow the movement of food from the stomach into the small intestine, particularly during treatment initiation.
Appetite regulation: They influence appetite-related pathways in the brain, contributing to reduced hunger and food intake.
Blood glucose management: They support improved glucose control in people with type 2 diabetes.
Common medications in this category include semaglutide, liraglutide, dulaglutide, and exenatide. Although they share similar mechanisms, their formulations, dosing schedules, and approved uses differ.
Research into GLP1 receptor agonists has expanded beyond blood glucose management. Scientists are investigating their potential effects on body weight, cardiovascular health, kidney function, and other metabolic processes. These areas are particularly important because type 2 diabetes and obesity are frequently associated with additional health complications.
Clinical studies have demonstrated that certain GLP1 receptor agonists can improve blood glucose control and support weight reduction. Some medications in this category have also demonstrated cardiovascular benefits in specific populations, particularly individuals with type 2 diabetes and established cardiovascular disease or elevated cardiovascular risk.
Important areas of ongoing research include:
Obesity management: Researchers are examining how appetite regulation and reduced calorie intake contribute to weight loss.
Cardiovascular health: Studies investigate changes in cardiovascular outcomes, including the risk of major cardiovascular events.
Kidney health: Research examines potential benefits for kidney function and the progression of chronic kidney disease in eligible populations.
Insulin resistance: Scientists are studying how improved glucose regulation and weight reduction influence insulin sensitivity.
Liver health: Research is evaluating the effects of GLP1-based treatments on metabolic dysfunction-associated steatotic liver disease and related conditions.
Despite their potential benefits, GLP1 receptor agonists have important safety considerations. Gastrointestinal side effects are among the most frequently reported reactions, particularly when treatment begins or dosage increases.
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Less common but serious concerns can include pancreatitis, gallbladder complications, and dehydration-related kidney problems.
The medications are not appropriate for everyone. Certain products also carry specific contraindications and warnings, including restrictions for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Researchers continue to investigate long-term safety, treatment effectiveness, individual responses, and the effects of discontinuing therapy. These findings help healthcare professionals understand the appropriate clinical applications of GLP1 receptor agonists and their role in managing metabolic conditions.